While irinotecan ( CPT-@ ) plus cisplatin ( CDDP ) combination therapy and CPT-@ monotherapy have been explored in the second-line setting , the superiority of second-line platinum-based therapies for AGC patients initially treated with S-@ monotherapy has not yet been evaluated ; therefore , we aimed to examine the survival benefit of CPT-@ / CDDP combination over CPT-@ monotherapy .